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Background: In Parkinson's disease (PD), the influence of chronic pain on motor features has never been
investigated. We have recently designed a technique that combines nociceptive system activation by
laser stimuli and primary motor cortex (M1) activation through transcranial magnetic stimulation (TMS),
in a laser-paired associative stimulation design (Laser-PAS). In controls, Laser-PAS induces long-term
changes in motor evoked potentials reflecting M1 long-term potentiation-like plasticity, arising from
pain-motor integration.
Objective: We here examined the possible influence of chronic pain on motor responses to Laser-PAS in
patients with PD, with and without chronic pain.
Methods: We compared motor responses to Laser-PAS in healthy subjects and in patients with PD, with
and without chronic pain.
Results: Unlike controls, we found reduced responses to Laser-PAS in patients with PD, with and without
pain. Patients off and on dopaminergic therapy had similar responses to Laser-PAS. When comparing
responses to Laser-PAS in patients with and without pain, the two patients' subgroups had similar ab-
normalities. When we compared patients with pain in the body region investigated with Laser-PAS, with
those with pain in other body regions, we found prominent changes in patients with homotopic pain.
Finally, when comparing Laser-PAS with the original PAS protocol, which combines electric peripheral
nerve stimuli and TMS, in patients without pain and those with homotopic pain, we found similar re-
sponses to both techniques in patients without pain, whereas Laser-PAS induced greater abnormalities
than PAS in patients with pain.
Conclusions: In PD, chronic pain degrades response to Laser-PAS through abnormal pain-motor
integration.
© 2017 Elsevier Inc. All rights reserved.DM, abductor digiti minimi;
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4.130Chronic pain is a non-motor symptom observed in 40e85% of
patients with Parkinson's disease (PD) [1e4]. In PD, chronic pain is
currently classified in nociceptive (i.e. muscoloskeletal, visceral and
cutaneus pain) and neurophatic pain (i.e. radicular and central
pain) [1,5,6]. Similarly to other non-motor symptoms in PD, pain is
currently considered to reflect extranigral pathology [7,8], but the
pathophysiology of chronic pain in PD remains largely unknown
[1,2,5,6,9].
Laser stimulation is widely considered a reliable tool for inves-
tigating pain pathways in humans [10]. Laser stimulation selec-
tively activates Ad and C nociceptors and evokes [11] scalp
potentials (LEPs) comprising an early lateralized component (N1),
generated by secondary sensory area (S2) area and a late negative-in the primary motor cortex in Parkinson's disease, Brain Stimulation
A. Suppa et al. / Brain Stimulation xxx (2017) 1e112positive complex (N2-P2) generated by anterior cingulate cortex
(ACC) [11e13]. Previous studies in patients with PD demonstrated
LEP abnormalities in patients with nociceptive and neuropathic
pain [14,15], suggesting abnormal cortical processing of nociceptive
inputs as a key pathophysiological mechanism underlying chronic
pain in PD [2,4,9].
Recently we have designed a new technique, namely Laser-
paired associative stimulation (Laser-PAS50) [16]. This protocol
combines laser pulses delivered to the hand with transcranial
magnetic stimulation (TMS) of M1 in a PAS design. In healthy
subjects, Laser-PAS50 elicits long-term increase of motor evoked
potential (MEP) amplitude through mechanisms of long-term
potentiation (LTP)-like plasticity in M1 possibly related to
changes in N-Methyl-D-aspartate transmission [16].
No studies have previously investigated M1 plasticity as
assessed with the Laser-PAS50 technique in PD with and without
chronic pain. A better understanding of pain-related M1 plasticity
might clarify the pathophysiological basis of chronic pain in PD and
open new perspectives in the treatment of this non-motor
symptom.
In this study, we applied Laser-PAS50 in a cohort of patients with
PD. Then to clarify whether in PD chronic pain influences the re-
sponses to Laser-PAS50, we compared Laser-PAS50 in patients with
and without pain. To understand whether pain has a segmental or
generalized effect, we compared responses to Laser-PAS50 in pa-
tients with pain in the right upper limb, the same body region
examined by Laser-PAS50, and patients with pain in other body
regions. Finally, to verify whether abnormal responses to Laser-
PAS50 in patients with chronic pain depends on intrinsic M1 plas-
ticity abnormalities regardless of the specific PAS protocol used, we
compared responses to Laser-PAS50 and to the original PAS proto-
col, which combines electric peripheral nerve stimuli and trans-
cranial magnetic stimulation (TMS) at interstimulus interval of
25ms (PAS25) [17], in the same cohort of patients, with and without
pain.
Material and methods
Subjects
Twenty patients with PD (14 men and 6 women, mean age±SD:
62.5 ± 9.5) and 20 age-matched healthy subjects (10 men and 10
women, mean age±SD: 59.7 ± 15.8) participated in the study. All
participants were right-handed. The diagnosis of idiopathic PD was
made according to the Queen Square Brain Bank criteria and the
EFNS/MDS-ES recommendations [18,19]. Patients were recruited
from the Movement Disorder Clinic at the Department of
Neurology and Psychiatry, Sapienza University of Rome. Patients
had a predominantly akinetic-rigid syndrome without dementia.
Patients were studied while they were under their usual dopami-
nergic treatment (on) and after drugs had been withdrawn for at
least 12 h (off). None of the patients received other neuropsychi-
atric medications. Patients were clinically evaluated before starting
each experimental session. Motor signs were scored using the
motor section of the Movement Disorders Society-Unified Parkin-
son's Disease Rating Scale (MDS-UPDRS) [20,21] and the Hoehn &
Yahr (H&Y) scale. Cognitive function was evaluated using the Mini
Mental State Evaluation (MMSE) [22] and the Frontal Assessment
Battery (FAB) [23]. Depression was assessed with the Hamilton
Depression Rating Scale (HAM-D) [24]. According to the criteria
suggested by Wasner et al. [5], we first evaluated the presence of
chronic pain. None of the healthy controls reported any type of
pain. Patients were asked to rate the intensity of pain on an 11-
point numerical rating scale (NRS) from 0 (no pain) to 10 (stron-
gest imaginable pain) [10] before the first experimental session andPlease cite this article in press as: Suppa A, et al., Pain-motor integration
(2017), http://dx.doi.org/10.1016/j.brs.2017.04.130relative to the previous 6 months. Those rating pain 4 and
reporting it from at least 6 months were considered “chronic-pain”
patients. Patients with chronic pain also underwent the screening
tool for the detection of neuropathic pain (La douleur neuropatique
en 4 questions - DN4) [25]. No patients were being administered
with any treatment for pain at the time of the study. Demographic
and clinical features of parkinsonian patients, with and without
pain are summarized in Table 1. Subjects gave their written
informed consent. The study was approved by the institutional
review Board of Sapienza, University of Rome, Italy and conformed
to the Declaration of Helsinki.
Laser stimulation technique and LEP recordings
Laser stimuli were delivered with a neodymium:yttrium-
aluminium-perovskite laser stimulator (Nd:YAP, wave length
1.34 mm, pulse duration 2e20 ms, maximum energy 7 J El.En -
Florence, Italy) under fiber-optic guidance. The laser perceptive
threshold was determined by increasing and decreasing the stim-
ulus energy in steps of 0.25 J in series of three stimuli, and defined
as the lowest intensity at which the subjects perceived at least the
50% of the stimuli [26]. To evoke clear and stable LEPs, laser stimuli
were set to induce a clear painful pinprick sensation (intensity
119.4e150 mJ/mm2; duration 5 ms; spot diameter 5 mm) and
directed to the ulnar region of the right hand dorsum. The target of
the laser beamwas shifted by at least 1 cm in a random direction, to
allow for passive skin cooling and avoid nociceptor fatigue or
sensitization and the interstimulus interval was varied pseudo-
randomly (10e15 s) [26]. Subjects, wearing protective goggles,
rested comfortably on a medical examination table. LEPs were
recorded through surface electrodes from the scalp: T3 referenced
to Fz for recording the early lateralized N1 component, and Cz
referenced to the nose, for recording the late vertex N2-P2 complex.
Electro-oculographic recordings monitored possible eye move-
ments or blinks. We averaged 15 artefact-free trials off line using
dedicated equipment (Synergy 10.1; EL.EN, Florence, Italy). The
recording bandpass was between 0.3 and 30 Hz and the sampling
frequency 50 kHz. We measured the peak latency and amplitude of
the lateralized N1 and the vertex N2-P2 complex. These methods
adhered to the recommendations given by the International
Federation of Clinical Neurophysiology [11]. LEP recordings were
taken at least 30 min before TMS, while the patients were on
therapy (1 h after taking their usually antiparkinsonian therapy).
TMS and MEP recordings
TMS was delivered through a repetitive magnetic stimulator
(Magstim Super Rapid-The Magstim Company Ltd, Whitland,
United Kingdom) connected to a figure-of-eight coil (external wing
9 cm in diameter) placed tangentially to the scalp on the left
hemisphere, with the handle pointing back and away from the
midline at 45 inducing postero-anterior and antero-posterior
biphasic currents in the brain. The coil was placed over the opti-
mum scalp position (hot spot) to elicit MEPs in the abductor digiti
minimi (ADM) muscle of the right hand. To ensure that the stim-
ulating coil remained in a constant position throughout the ex-
periments, the hot spot was marked on the scalp with a soft-tipped
pen. Motor threshold was determined at rest (RMT) as the lowest
intensity able to evoke a MEP of more than 50 mV in at least 5 of 10
consecutive trials in the ADMmuscle. RMTwas determined in steps
of 1% maximum stimulator output intensity. Electromyographic
activity was recorded through a pair of surface electrodes placed
over the right ADM muscle, using a belly-tendon montage. Elec-
tromyographic raw signals were recorded, sampled at 5 kHz with a
CED 1401 A/D laboratory interface (Cambridge Electronic Design,in the primary motor cortex in Parkinson's disease, Brain Stimulation
Table 1
Demographic and clinical features of 20 patients with Parkinson's disease (PD), with and without chronic pain, participating into the experiments. Note that 15 out of 20
patients (75%) reported chronic pain and none of the patients reported neuropathic pain. MDS-UPDRS: Movement Disorders Society-Unified Parkinson's Disease Rating Scale;
H&Y: Hoehn & Yahr scale. MMSE: Mini Mental State Evaluation; FAB: Frontal Assessment Battery; HAM-D: Hamilton Depression Rating Scale; LEDDs: L-Dopa equivalent daily
doses (mg) calculated for each patient according to the criteria of Tomlinson et al. [88]; RUL: right upper limb; DN4: Neuropathic Pain in 4 questions; NRS: numerical rating
scale for pain; AV: average. SD: standard deviation. The 0 scores from the questionnaire for the detection of neuropathic pain (DN4) are not shown.
Patient Age
(years)
Gender Disease Duration UPDRS H&Y MMSE FAB HAM-D LEDDs ChronicPain RUL Pain DN4 NRS
On Off
1 71 M 1 22 32 2 28 16 2 300 e e e e
2 74 M 14 9 30 2 30 17 2 850 þ e 1 4
3 69 M 5 26 40 2 24 14 5 650 e e e e
4 80 M 7 11 20 1 30 16 0 550 þ þ 0 6
5 48 F 7 20 30 2 30 18 3 405 þ e 0 7
6 61 F 8 21 32 2 28 17 3 460 e e e e
7 63 F 7 18 33 2 30 18 2 400 þ þ 0 8
8 59 M 1 4 12 1 30 18 7 310 þ þ 0 4
9 69 M 5 12 20 2 30 18 0 310 e e e e
10 60 M 2 10 12 1 30 18 0 260 e e e e
11 69 M 10 17 40 2 28 17 2 942 þ þ 0 5
12 63 M 7 8 22 1 30 18 3 400 þ þ 0 6
13 62 M 3 14 25 2 30 18 7 310 þ e 0 4
14 60 F 5 12 20 2 30 18 7 405 þ e 0 5
15 58 M 1 11 16 2 30 18 7 160 þ e 0 5
16 40 F 3 35 38 1 30 18 20 310 þ þ 3 5
17 75 M 2 20 23 1 29 8 13 400 þ þ 3 7
18 61 M 1 22 26 1 30 18 4 400 þ þ 0 5
19 53 M 1 14 15 1 30 17 7 340 þ þ 0 4
20 55 F 2 16 20 1 30 18 0 300 þ þ 0 5
Av 62.5 4.6 16.1 25.3 1.6 29.4 16.9 4.7 423.1 0.5 5.3
SD 9.5 3.6 7.2 8.8 0.5 1.5 2.3 4.9 193.0 1.1 1.2
A. Suppa et al. / Brain Stimulation xxx (2017) 1e11 3Cambridge, UK), amplified (1000), and filtered (bandwidth 5-
1 kHz) with the Digitimer D360 (Digitimer Ltd., Welwyn Garden
City, Hertfordshire, UK) and stored on a laboratory computer for on-
line visual display and further off-line analysis (Signal software,
Cambridge Electronic Design, Cambridge, UK). The baseline elec-
tromyographic activity level before, during and after TMS was
controlled by visual-feedback through an oscilloscope screen and
auditory feedback through a loudspeaker. To exclude possible
confounding effects from involuntary muscular contraction, trials
with background electromyographic activity were rejected. MEP
amplitude was measured peak-to-peak (mV) and then averaged.Experimental design
The study consisted of two separate experimental sessions
(Experiments 1e2; Fig. 1). All controls and patients participated in
Experiment 1, whereas a subgroup of 10 patients participated in
Experiments 2. All experimental sessions took place at comparable
daytime and at least 1 week elapsed between each session. Par-
ticipants were tested fully relaxed and with their eyes open.Experiment 1: Effect of Laser-PAS50
In this experiment, designed to investigate the response to
Laser-PAS50 protocol in healthy controls and patients with PD, with
and without pain, when off and on therapy, we used a “test-con-
ditioning” TMS approach. The “test” stimulation consisted of 20
single TMS pulses able to elicit MEPs of 1 mV from the right ADM at
baseline (T0). We then recorded and measured a clear-cut peak LEP
N1 component according to the international recommendations
[11]. We applied “conditioning” Laser-PAS50 consisting of 60 re-
petitive TMS pulses at 0.1 Hz, each TMS pulse following a single
laser stimulus delivered at an interstimulus interval of LEP N1
latencyþ50 ms (total duration of intervention: 10 min) [16]. Laser
stimuli were delivered at the same intensity used during LEP
recording. To investigate the time course of after-effects induced byPlease cite this article in press as: Suppa A, et al., Pain-motor integration
(2017), http://dx.doi.org/10.1016/j.brs.2017.04.130Laser-PAS50, we compared baseline MEPs (T0) with those recorded
immediately after Laser-PAS50 ended (T1) and at 10 (T2), 20 (T3), 30
(T4), 40 (T5), 50 (T6) and 60 (T7) after it ended. All patients were
studied at T1-T7. Patients were randomly assigned to participate in
two separate sessions, when off and on therapy.Experiment 2: Effect of Laser-PAS50 and PAS25
This experiment was designed to compare responses to Laser-
PAS50 and to PAS25 protocol in patients with PD, with and without
pain, while they were on therapy. A subgroup of 10 patients, 5 with
pain in the right upper limb, and 5 patients without pain partici-
pated in two separate experimental sessions (Laser-PAS50 and
PAS25), randomly. We delivered Laser-PAS50 as described in
Experiment 1, and recorded 20 MEPs before (T0) and after condi-
tioning (T1eT7). PAS25 was delivered using peripheral ulnar nerve
electric stimulation (cathode proximal) and TMS over the cortical
hot-spot for ADM at an interstimulus interval of 25 ms. The in-
tensity of TMS was set to evoke anMEP of 1 mV in the ADMmuscle,
while the intensity of the ulnar nerve stimulus (0.2 ms duration)
was set at 3 times perceptive threshold (by calculating the mini-
mum intensity at which 5 electric stimuli, delivered over the ulnar
nerve at the wrist, are all clearly perceived). Two hundred pairs of
stimuli were given at 0.25 Hz. MEPs were recorded from the ADM
muscle at baseline (T0) and at T1-T7 after PAS25, and then averaged.Statistical analysis
We used the unpaired Student's t-test to compare the RMT, the
intensity to evoke baseline MEPs and for Laser-PAS50, heat sensa-
tion, the intensity of laser pulse during Laser-PAS50, the latency and
amplitude of MEP and of main LEP components (N1 and N2/P2), in
controls and in patients, when off and on therapy. To assess the
effect of dopaminergic therapy on MEP and LEP measurements we
used the paired Student's t-test.in the primary motor cortex in Parkinson's disease, Brain Stimulation
Fig. 1. Experimental paradigm. Experiment 1 began with laser-evoked potentials (LEPs) recordings. We tested the excitability of the primary motor cortex (M1) recording 1 mV
motor evoked potentials (MEPs). We then applied 10 min of Laser-PAS50 and examined long-term changes in MEP amplitude, for 60 min after Laser-PAS50 ended, in healthy subjects
(HS) and patients with Parkinson's disease (PD), with and without pain, off and on therapy. In the experiment 2, we compared MEPs before (T0) and for 60 min following Laser-
PAS50 and PAS25 in a subgroup of patients with PD with chronic pain in the right upper limb and in a subgroup of PD patients without pain. MEPs were recorded from the right
abductor digiti minimi muscle (ADM).
A. Suppa et al. / Brain Stimulation xxx (2017) 1e114In Experiment 1, to test the effect of Laser-PAS50 on MEP
amplitude in controls and patients, off and on therapy, we used
between-group analysis of variance (ANOVA) with “Group”
(healthy subjects vs patients off therapy, healthy subjects vs pa-
tients on therapy) and “Time” (T0 vs T1-T7). To clarify the effect of
dopaminergic therapy on responses to Laser-PAS50 in patients, we
also used the two-ways repeated-measures ANOVA with factor
“dopaminergic therapy” (off vs on) and factor “Time”. In a subse-
quent analysis, to assess the effect of chronic pain on plasticity
induced by Laser-PAS50 in patients, off and on therapy, we used two
separate between-group ANOVAs with factor “Pain” (patients with
vs patients without pain, off and on therapy) and “Time”. To assess
the effect of chronic pain in homotopic and heterotopic body re-
gions in PD, we first compared responses to Laser-PAS50 in controls
and patients with homotopic or heterotopic pain, off and on ther-
apy, by using separate between-group ANOVAs with factor “Group”
(healthy subjects vs patients with pain in the right upper limb or
patients with pain in other body regions, off and on therapy) and
factor “Time”. Then, we also used two separate between-group
ANOVAs with factor “Pain Localization” (patients with pain in the
right upper limb vs patients with pain in other body regions, off and
on therapy) and “Time” to better assess the specific effect of chronic
pain in homotopic and heterotopic body regions in patients, off and
on therapy.
In the Experiment 2, to compare the effect of Laser-PAS50 and
PAS25 on MEP amplitude in patients with chronic pain in the right
upper limb, and in patients without chronic pain, on therapy, we
used a mixed-design ANOVA with “Group” (patients with pain in
the right upper limb vs patients without pain), “Protocol” (Laser-
PAS50 vs PAS25) and “Time” (T0 vs T1-T7) as main factors of analysis.
We used the Spearman's R correlation test to assess correlation
between patients' clinical features (UPDRS, MMSE, FAB, HAM-D,
NRS, disease duration and total L-Dopa equivalent daily doses -
LEDDs) and changes in MEP amplitude induced by Laser-PAS50
respect to baseline (T0), at all time intervals. P values less than 0.05Please cite this article in press as: Suppa A, et al., Pain-motor integration
(2017), http://dx.doi.org/10.1016/j.brs.2017.04.130were consider to be statistically significant. The Greenhouse-
Geisser correction was used when necessary to correct the non-
sphericity.
All data are reported as average ± SD.
Results
None of the subjects experienced any adverse effects during or
after the Laser-PAS50. All subjects perceived laser stimuli as painful
in all experimental sessions and had LEP values within the
normative ranges established in our laboratory [11,26].
In our cohort of patients, 15 out of 20 patients (10 men and 5
women, mean age±SD: 61.3 ± 10.4) reported at least one type of
chronic pain (patient number 2, 4e5, 7e8, 11e20), all of them
underwent the DN4 questionnaire and obtained a score <4, thus
excluding the presence of neuropathic pain (Table 1).
The Student's t-test showed comparable RMT, TMS intensity,
perceptive threshold, laser pulse intensity, latency and amplitude
of MEPs and LEPs, in controls and in patients, when off and on
therapy (all p values > 0.05) (Tables 2 and 3).
Experiment 1
ANOVA showed that, after Laser-PAS50, MEPs increased in
amplitude at T1-T7 in healthy controls, whereas in patients it
remained unchanged. The amount of MEP changes induced by
Laser-PAS50 differed in healthy controls and in patients off therapy.
ANOVA showed a significant interaction between factors “Group”
and “Time” (F7.266 ¼ 6.16; p < 0.001), and a significant effect of
factor “Group” (F1.38 ¼ 6.13; p ¼ 0.02) and “Time” (F7.266 ¼ 8.67;
p < 0.001). In controls, ANOVA showed a significant effect of the
factor “Time” (F7.133 ¼ 8.34; p < 0.001); after Laser-PAS50, MEP
amplitude increased significantly at T2-T7 (p < 0.01 for all com-
parisons). By contrast, in patients off therapy, the factor “Time” was
not significant (F7.133 ¼ 1.02; p ¼ 0.42). Although MEP amplitudein the primary motor cortex in Parkinson's disease, Brain Stimulation
Table 3
Transcranial magnetic stimulation (TMS) data in the experiment testing primary
motor cortex (M1) plasticity in 20 healthy subjects (HS) and in 20 patients with
Parkinson's disease (PD), off and on therapy. RMT¼ Resting motor threshold; Int. for
MEPs ¼ Intensity for 1 mv MEP.
RMT (%) Int. for MEPs (%)
Controls 41.1 ± 4.9 54.7 ± 9.4
PD off 41.3 ± 15.2 54.3 ± 20.2
PD on 43.9 ± 15 57.2 ± 17.4
A. Suppa et al. / Brain Stimulation xxx (2017) 1e11 5was similar at T0 in controls and patients off therapy, after Laser-
PAS50, MEP amplitude differed significantly at T2-T7 in the two
groups (p < 0.05 for all comparisons) (Fig. 2).
Comparing healthy controls and patients on therapy, ANOVA
showed significant interaction between factors “Group” and “Time”
(F7.266 ¼ 4.80; p < 0.001), and a significant effect of factor “Group”
(F1.38 ¼ 7.10; p ¼ 0.01) and “Time” (F7.266 ¼ 9.48; p < 0.001). In
controls, ANOVA confirmed a significant effect of the factor “Time”
(F7.133 ¼ 8.34; p < 0.001); after Laser-PAS50, MEP amplitude
significantly increased at T2-T7 (p < 0.01 for all comparison). By
contrast, in patients on therapy, the factor “Time” was not signifi-
cant (F7.133¼ 1.50; p ¼ 0.17). Although MEPs were comparable at T0
in healthy subjects and patients on therapy, after Laser-PAS50, MEPs
differ at T2-T7 (p < 0.05 for all comparison) (Fig. 2).
When we assessed the effect of dopaminergic therapy in pa-
tients, ANOVA showed no significant effect of the factor “dopami-
nergic therapy” (F1.19 ¼ 0.62; p ¼ 0.44) nor the effect of the factor
“Time” (F7.133 ¼ 1.26; p ¼ 0.22) (Fig. 2).
When testing the effect of chronic pain on responses to Laser-
PAS50 in patients, off and on therapy, ANOVA showed a non sig-
nificant effect of the factor “Pain” (F1.18¼ 0.26; p¼ 0.62) and “Time”
(F7.126 ¼ 0.63; p ¼ 0.73) when off and on state of therapy
(F1.18 ¼ 0.22; p ¼ 0.65 and F7.126 ¼ 1.24; p ¼ 0.29, respectively)
(Fig. 3).
Comparing controls with patients with pain in the right upper
limb (n ¼ 10, patient number 4, 7, 8, 11, 12 and 16e20), ANOVA
showed a significant interaction between factors “Group” and
“Time”, when off and on therapy (F7.196 ¼ 3.01; p < 0.01 and
F7.196 ¼ 4.07; p < 0.01, respectively) and a significant effect of factor
“Group” (F1.28 ¼ 4.22; p < 0.01 and F1.28 ¼ 6.38; p < 0.01, respec-
tively) and “Time” (F7.196¼ 5.07; p < 0.01 and F7.196¼ 3.58; p < 0.01,
respectively). Post hoc analysis showed that MEPs increased in
amplitude at T3-T7 (all p values < 0.05) in controls but not in pa-
tients with pain in the right upper limb, when off and on therapy.
Differently, when we tested responses to Laser-PAS50 in controls
and patients with pain in other body regions (n¼ 5, patient number
2, 5, 13, 14, 15), off and on therapy, ANOVA showed a significant
effect of the factor “Time” (F7.16 ¼ 4.80; p < 0.01 and F7.16 ¼ 4.53;
p < 0.01, respectively), whereas factor “Group” (F1.23¼ 0.46; p¼ 0.5Table 2
Analytical results for Laser-evoked potential (LEP) recordings in the 20 patients with Park
Patients Perceptive Stim Int. N1 lat.
Threshold (mJ/mm2) (mJ/mm2) (ms)
1 51 102 188
2 51 127 200
3 70 153 198
4 76 153 220
5 38 102 152
6 64 127 182
7 39 115 220
8 51 127 188
9 50 127 216
10 50 114 218
11 38 127 220
12 51 127 138
13 50 127 198
14 51 127 188
15 40 140 244
16 38 102 186
17 38 127 164
18 25 178 230
19 76 153 178
20 51 127 193
Av 49.9 129.1 195.05
SD 13.3 19.1 26.4
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(2017), http://dx.doi.org/10.1016/j.brs.2017.04.130and F1.23 ¼ 0.67; p ¼ 0.42, respectively) and the interaction be-
tween “Group” and “Time” (F7.161 ¼ 0.49; p ¼ 0.84 and F7.161 ¼ 0.52;
p ¼ 0.82, respectively) were both non significant.
When comparing responses to Laser-PAS50 in patients, off and
on therapy, with pain in the right upper limb with patients with
pain in other body regions, ANOVA showed a significant interaction
between factors “Pain Localization” and “Time” (F7.91 ¼ 3.33;
p < 0.01) and a significant effect of the factor “Pain Localization”
(F1.13¼ 4.68; p¼ 0.04) and “Time” (F7.91¼6.46; p < 0.01) in patients
off therapy. Post hoc analysis showed that MEPs decreased in
amplitude at T3-T5 (all p values < 0.05) in patients with pain in the
right upper limb compared with patients with pain in other body
regions. Similarly, in patients on therapy ANOVA showed a signif-
icant interaction between factors “Pain Localization” and “Time”
(F7.91 ¼ 2.39; p ¼ 0.03) and a significant effect of the factor “Pain
Localization” (F1.13 ¼ 7.64; p ¼ 0.02) and “Time” (F7.91 ¼ 2.20;
p ¼ 0.04). Post hoc analysis showed that MEPs decreased in
amplitude at T4-T7 (all p values < 0.05) in patients with pain in the
right upper limb compared with patients with pain in other body
regions (Fig. 4).
Experiment 2
In the Experiment 2, ANOVA showed a significant effect of the
factor “Protocol” (F1.8 ¼ 8.48; p ¼ 0.02) and “Time” (F7.56 ¼ 3.61;
p < 0.01). In patients with pain in the right upper limb, post hoc
analysis showed an interaction between the factors “Protocol” and
“Time” (F7.28 ¼ 4.07; p < 0.01) and a significant effect of the factor
“Protocol” (F1.4 ¼ 139.98; p < 0.01) and “Time” (F7.28 ¼ 4.40;inson's disease (PD). Stim. Int: Stimulation Intensity; Lat: Latency; Amp: Amplitude.
N1 amp. N2 lat. N2 amp. P2 lat. P2 amp.
(mV) (ms) (mV) (ms) (mV)
8.6 210 9.2 314 13.2
5.0 240 4.0 350 8.0
3.0 236 7.0 438 2.0
6.5 284 4.5 420 16.0
6.0 194 16.0 330 14.0
3.0 216 4.0 298 20.0
6.0 248 10.0 350 18.0
10.0 239 7.2 360 13.0
6.0 244 6.0 318 1.5
13.0 252 7.0 366 6.0
5.0 240 10.0 395 7.5
9.0 180 8.0 300 12.0
6.5 238 13.0 358 7.0
6.0 230 3.0 294 9.0
5.0 246 8.4 390 7.0
5.0 244 1.0 330 17.0
1.0 223 6.0 356 14.0
4.3 274 4.3 384 6.0
13.2 226 9.6 318 22.6
6.5 230 7.0 350 9.0
6.4 234.7 7.26 350.95 11.1
3.1 23.7 3.5 41.0 5.8
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Fig. 3. Effect of Laser-PAS50 on motor evoked potential (MEP) amplitude in patients with Parkinson's disease (PD), with and without pain, off and on therapy. Each point corre-
sponds to the mean MEP amplitude recorded at baseline and for 60 min after Laser-PAS50. Vertical bars represent SD. Note that Laser-PAS50 induced no changes on MEP amplitude in
PD patient, with and without pain, off and on therapy.
Fig. 2. Effects of Laser-PAS50 on motor evoked potential (MEP) amplitude in healthy subjects (HS) and in patients with Parkinson's disease (PD), off and on therapy. Each point
corresponds to the mean MEP amplitude recorded at baseline and for 60 min after Laser-PAS50. Vertical bars represent SD. Asterisks indicate significant P values. Note that Laser-
PAS50 increased MEP amplitude in healthy subjects but not in patients with PD, off and on therapy.
A. Suppa et al. / Brain Stimulation xxx (2017) 1e116p < 0.01). Although in patients with pain in the right upper limb,
MEPs were comparable before Laser-PAS50 and PAS25 (T0) (p ¼ 1),
compared to PAS25, Laser-PAS50 elicited lower amplitude MEPs at
T2-T7 (all p values < 0.05). Conversely, in patients without pain,
post hoc analysis showed a non significant effect of the factors
“Protocol” (F1.4 ¼ 0.81; p ¼ 0.42) and “Time” (F7.28 ¼ 1.58; p ¼ 0.18)
demonstrating that MEPs were comparable before and after Laser-
PAS50 and PAS25 (all p > 0.05) (Fig. 5).
The Spearman's R correlation test found no correlation between
patients' clinical features at all the time intervals. In contrast,
Spearman's correlation test showed a significant negative correla-
tion between the severity of pain reported in the right upper limb,
as assessed by the NRS, and the percentage of MEP amplitude in-
crease at T5 after Laser-PAS50 in patients off (R ¼ 0.78 and
p ¼ 0.01) and on therapy (R ¼ 0.70 and p ¼ 0.02) (Fig. 6A and B).
Discussion
In this study, we demonstrated abnormal MEP responses to
Laser-PAS50 in PD. Dopaminergic therapy left responses to Laser-
PAS50 globally unchanged. The response to Laser-PAS50 wasPlease cite this article in press as: Suppa A, et al., Pain-motor integration
(2017), http://dx.doi.org/10.1016/j.brs.2017.04.130comparable in patients with and without chronic pain. In patients
with pain in the limb directly investigated with Laser-PAS50, we
found prominent abnormal responses than in patients with pain in
other body regions. We provide here the first evidence of a reduced
responses to Laser-PAS50 in patients with and without chronic pain,
off and on therapy, reflecting an altered pain-motor integration.
When testing the effects of Laser-PAS50 in PD, we have excluded
a number of methodological factors possibly leading to misinter-
pretation of our data. Given that we found comparable RMT values,
intensity to evoke MEPs of 1 mV amplitude and intensity for TMS
during Laser-PAS50, in healthy controls and patients, off and on
therapy, we excluded possible confoundings due to altered integ-
rity of the cortico-spinal tract as well as difference in M1 baseline
excitability. We also used comparable laser intensity during Laser-
PAS50, in controls and patients, off and on therapy. During each
experimental session, we checked the patients' muscle relaxation
and none of the patients showed voluntary or involuntarymuscular
activity before, during or after Laser-PAS50 excluding homeostatic
or non-homeostatic interaction betweenmuscular activity and TMS
[27e31]. In this study, whenwe applied repeated sessions of Laser-
PAS50 in the same patient, we used between-session intervals of atin the primary motor cortex in Parkinson's disease, Brain Stimulation
Fig. 4. Effect of Laser-PAS50 on motor evoked potential (MEP) amplitude in patients with Parkinson's disease (PD), with pain in the right upper limb or in other body regions. Each
point corresponds to the mean MEP amplitude recorded at baseline and for 60 min after Laser-PAS50. Vertical bars represent SD. Asterisks indicate significant P values (significant
values at T3-T5 in patients off, and at T4-T7 in patients on therapy). Note that Laser-PAS50 induced no changes in MEP amplitude in all patients' subgroups. However, Laser-PAS50
induced lower responses in patients with pain in the right upper limb than those observed in patients with pain in other body regions, off and on therapy.
Fig. 5. Effect of Laser-PAS50 and PAS25 on motor evoked potential (MEP) amplitude in patients with Parkinson's disease (PD), with pain in the right upper limb and in patients
without pain, on therapy. Each point corresponds to the mean MEP amplitude recorded at baseline and for 60 min after Laser-PAS50 and PAS25. Vertical bars represent SD. Asterisks
indicate significant P values. Note that Laser-PAS50 and PAS25 induced comparable changes in PD patients without pain, whereas in PD patients with pain in the right upper limb
they did not. Compared to PAS25, Laser-PAS50 induced lower responses in patients with pain in the right upper limb than those observed in patients without pain, on therapy.
A. Suppa et al. / Brain Stimulation xxx (2017) 1e11 7least one week making highly unlikely the possible interference
between the two experimental sessions [28,31,32].Laser-PAS50 elicits reduced responses in Parkinson's disease
The reduced responses to Laser-PAS50 we observed in patients
off therapy, may reflect a number of pathophysiological mecha-
nisms. We can reasonably exclude a significant contribution of
small-nerve fibre damage, previously demonstrated in a skin bi-
opsy study in patients with PD [33] since none of the participants
manifested or referred any dysautonomic symptom and none had
pure neuropathic pain. Moreover, we found comparable laser
perceptive thresholds, latency and amplitude of N1- and N2/P2-LEP
components in healthy controls and in patients, with and without
pain. Similar laser perceptive thresholds and latency/amplitude of
the N1 and N2/P2-LEP components in healthy controls and in pa-
tients, with and without pain, also exclude damage of peripheral
and central nociceptive afferent pathways. These data therefore
indicate that our patients with pain did not suffer from neuropathicPlease cite this article in press as: Suppa A, et al., Pain-motor integration
(2017), http://dx.doi.org/10.1016/j.brs.2017.04.130pain [34]. The observation of comparable LEP amplitudes in con-
trols and in patients with PD argues against two previous laser
studies, that using a CO2 laser stimulator reported abnormal LEPs in
PD. Schestatsky et al. [14] found an increased LEP amplitude in
patients with PD with neurophatic (central) pain; conversely,
Tinazzi et al. [15] stimulating the shoulder, reported a decreased
LEP amplitude in patients with nociceptive (muscoloskeletal) pain.
In our study, however, we used a different laser stimulator, inves-
tigated the hand and none of our patients suffered from neuro-
phatic (central) pain, as assessed with DN4. Hence, the hypothesis
that possible changes in N2/P2 LEP component influenced our
findings is very unlikely. A more likely hypothesis implies that the
reduced responses to Laser-PAS50 we observed in patients, off
therapy, reflects changes in M1 plasticity mechanisms. In a previ-
ous study in healthy subjects [16], we found that, Laser-PAS50 in-
duces MEP amplitude changes that might reflect spike-timing-
dependent plasticity (STDP) in M1 [16,17]. STDP in M1 is sup-
posed to reflect the coincidence detection of excitatory post-
synaptic potentials in the apical dendrites (layer 2/3) and back-in the primary motor cortex in Parkinson's disease, Brain Stimulation
Fig. 6. Correlation between the amount of pain as assessed by the numerical rating scale for pain (NRS), and the MEP amplitude recorded at T5 (40 min after the end of Laser-PAS50),
in patients with Parkinson's disease (PD), with pain in the right upper limb, off (A) and on therapy (B). Note the negative correlation between pain severity as tested by NRS and the
amount of MEP amplitude changes following Laser-PAS50 in patients with PD off (A) and on therapy (B).
A. Suppa et al. / Brain Stimulation xxx (2017) 1e118propagating action potentials from layer 5 neurons [16,35e38].
Since TMS activates layer 5 cortical-spinal neurons [39,40] and
cortical projections originating from remote cortical pain-related
areas reach M1 in cortical layers 2/3 [41e43], it is likely that
Laser-PAS50 induces STDP in cortical layer 2/3 of M1. Hence, the
hypothesis we favor is that in PD patients off therapy, the reduced
response to Laser-PAS50 reflects abnormal STDP in M1.Dopaminergic therapy does not restore responses to Laser-PAS50
We found that L-Dopa left responses to Laser-PAS50 unchanged
in patients with and without chronic pain, suggesting that dopa-
minergic therapy does not restore abnormal STDP in M1 in PD, in
line with previous observations with other types of plasticity-
inducing protocols [16,44e48]. Our findings indirectly support
the hypothesis that non-dopaminergic pathways contribute to the
pathophysiology of pain in PD [2,4]. Extranigral pathology in PD,
including neurodegeneration in the noradrenergic, serotonergic,
and cholinergic systems, contributes to pain modulation
[7,8,49,50]. The hypothesis that a non-dopaminergic pathway
contributes to the pathophysiology of chronic pain in PD is also inPlease cite this article in press as: Suppa A, et al., Pain-motor integration
(2017), http://dx.doi.org/10.1016/j.brs.2017.04.130line with the observation that dopaminergic therapy only partly
improve pain [2,4].The response to Laser-PAS50 differs according to pain localization in
Parkinson's disease
When comparing patients with chronic pain (regardless of the
specific body region affected by pain) and patients without pain, we
found comparable responses to Laser-PAS50 in the two groups. This
observation would suggest that in PD, chronic pain does not in-
fluence per se the response to Laser-PAS50. When we compared
however, patients with pain in the right upper limb and patients
with pain in other body regions (but not in the right upper limb),
we found different responses to Laser-PAS50 in the two patients'
subgroup: patients with pain in the right upper limb had promi-
nent alterations in responses to Laser-PAS50, whereas patients with
pain in other body regions were characterized by less severe
neurophysiological abnormalities. It should be noted, that in our
analysis, we found different responses to Laser-PAS50 when
comparing controls and patients with homotopic but not hetero-
topic pain probably due to the low number of subjects analysed in
the third group (controls: n ¼ 20; patients with homotopic pain:in the primary motor cortex in Parkinson's disease, Brain Stimulation
A. Suppa et al. / Brain Stimulation xxx (2017) 1e11 9n ¼ 10; patients with heterotopic pain: n ¼ 5). Interestingly, we
found a negative correlation between the severity of pain in the
right upper limb, as tested by NRS scores, and the amount of
response to Laser-PAS50. Given that patients with pain in the right
upper limb had similar clinical features including MDS-UPDRS
motor scores compared to those with pain in other body regions,
we can exclude that the prominent abnormalities in MEP changes
observed after Laser-PAS50, in patients with pain in the right upper
limb, merely arised frommore severemotor symptoms. Overall our
findings demonstrate that in patients with chronic pain, the
severity of M1 STDP abnormalities is prominent when Laser-PAS50
examines the body region specifically affected by pain further
suggesting abnormal pain-motor integration in PD.
Pain-motor and sensori-motor integration in Parkinson's disease
The reduced responses to Laser-PAS50 might arise from
abnormal STDP in M1 that does not strictly depend on the specific
PAS protocol used. Previous studies with the original PAS25 protocol
have demonstrated abnormal responses to PAS25 in PD
[45,48,51e59]. In more detail, the response to PAS25 has been
consistently found to be reduced in PD following PAS25 over the
most affected M1, as in our study. According to the hypothesis that
the reduced responses to Laser-PAS50 arise from abnormalM1 STDP
not strictly depending on the specific PAS protocol used, patients
with PD, with and without pain, should have manifested compa-
rable responses to Laser-PAS50 and PAS25, since both PAS protocols
are known to elicit STDP in M1. In this study, however, this was not
the case. In our second set of experiments, we found comparable
responses to Laser-PAS50 and PAS25 only in patients without pain.
By contrast, in patients with homotopic pain, Laser-PAS50 elicited
greater abnormalities than PAS25. Previous studies have shown that
chronic musculoskeletal pain may lead to cortical reorganization
processes in M1 muscle representation [60e63]. Accordingly, it
might be argued that in PD, pain-induced cortical reorganization
contributed to the differential response to Laser-PAS50 and PAS25
we observed in patients with homotopic pain. In this study, we did
not examine and compare cortical maps of ADMmuscles in patients
with andwithout pain and thuswe cannot fully exclude that a pain-
related cortical map reorganization might have contributed at least
in part to our findings. However, this hypothesis seems unlikely
since in PD patients with homotopic pain, a pain-induced cortical
reorganization would have similarly affected responses to both
Laser-PAS50 and PAS25 protocols. We therefore suggest that the
reduced responses to Laser-PAS50 in patients with homotopic pain
reflect abnormal M1 SDTP specifically induced by the activation of
the nociceptive system. Hence, we suggest that in PD, and specif-
ically in patients with chronic pain, the reduced responses to Laser-
PAS50 reflect abnormal pain-motor integration processes in func-
tionally connected brain regions involved in pain matrices. In the
present study, we did not compared pain-motor integration and
sensori-motor integration in patients with chronic pain in other
body regions because this subgroup of patients was characterized
by heterogeneous pain localization, thus precluding a precise
evaluation of pain-motor integration processes. Accordingly, the
possible effect of heterotopic pain on pain-motor integration pro-
cesses in patients with PD remains to be clarified.
Brain networks underlying abnormal pain-motor integration in
Parkinson's disease
In a previous study in healthy subjects [16], we have suggested
that Laser-PAS50 elicits STDP in M1 through mechanisms of pain-
motor integration reflecting the functional connectivity between
pain and motor areas involved in the pain matrix (ACC, insula, S2,Please cite this article in press as: Suppa A, et al., Pain-motor integration
(2017), http://dx.doi.org/10.1016/j.brs.2017.04.130supplementary motor area and M1). The pain matrix is thought to
be responsible for cortical processing and conscious experience of
pain [12,64e67]. Experimental evidence in animals and also in
humans have demonstrated that most of the cortical areas
contributing to the pain matrix are also targeted by dopaminergic
projections including the “mesolimbic” and “mesocortical” dopa-
minergic pathways and that those pathways play a role in noci-
ception [68,69]. Previous studies in healthy subjects with positron
emission tomography have demonstrated increased dopaminergic
release following various types of experimental pain [70e74]. In
patients with PD, a study with functional magnetic resonance
imaging demonstrated increased pain-induced activation of the
right insula, prefrontal and left ACC in patients off therapy, but
reduced activation in the same cortical areas in the on state of
therapy, compared with controls [75]. Overall these findings
support the hypothesis that in PD, altered mesolimbic and mes-
ocortical dopaminergic pathways influence the activation of the
pain matrix possibly leading to abnormal cortical pain-motor
integration. Whether one specific cortical area, among those
contributing to the pain matrix is responsible of abnormal cortical
pain-motor integration in PD, remains to be clarified. It remains
also unclear whether abnormal cortical pain-motor integration
might predispose or contribute to the pathophysiology of chronic
pain in PD.
A further comment concerns the possibility that in PD, abnormal
pain-motor integration may occur also in subcortical brain regions.
Experimental studies in animals and in humans have demonstrated
that dopamine exerts a key role in modulating the “brainstem
descending pain-modulatory system” [70e74,76]. Hence, in PD,
dopaminergic degeneration in the substantia nigra pars compacta
might drive an altered activation of the “brainstem descending
pain-modulatory system” leading to abnormal pain-motor inte-
gration in the spinal cord. Furthermore, in PD, abnormal painmotor
integration might occur also at basal ganglia level since dopami-
nergic denervation changes the release of neuropeptides contrib-
uting to nociception. It is known that striatal medium spiny
neurons that give rise to the “direct pathway” release substance P
and dynorphin, whereas those involved in the “indirect pathway”
release enkephalin [77e79]. Experimental studies in animals have
demonstrated that neurons in the substantia nigra, caudate, puta-
men and globus pallidus clearly respond to noxious stimulation
[9,80,81]. In addition, the basal ganglia receive nociceptive infor-
mation also directly from the cortex, thalamus and amygdala
[9,80,81]. The laser-PAS50 technique however, has been designed to
examine specifically cortical pain-motor integration processes.
Future studies would clarify the possible pathophysiological role of
abnormal pain-motor integration processes at brainstem and basal
ganglia level.
When interpreting our neurophysiological observations in PD,
with and without chronic pain, several limitations should be taken
into account. Given that we recorded LEPs in all patients on therapy,
we cannot exclude a possible effect of dopaminergic therapy on N1
and N2/P2 LEP components in patients with and without pain. This
hypothesis however, seems unlikely as suggested by a previous LEP
study [82]. Future studies however, will clarify possible changes in
pain-motor integration in drug naïve patients with PD, thus
excluding possible confounding factors secondary to dopaminergic
treatments. In our cohort of patients with PD, we studied no pa-
tients with a neuropathic pain including the central parkinsonian
pain [4]. Hence, we cannot clarify whether the response to Laser-
PAS50 may differ in patients with nociceptive or neuropathic pain.
Future studies will clarify whether the nociceptive or neuropathic
pain component predominantly contribute to the abnormal
response to Laser-PAS50 in PD.in the primary motor cortex in Parkinson's disease, Brain Stimulation
A. Suppa et al. / Brain Stimulation xxx (2017) 1e1110Conclusions
In this study, we report abnormal responses to Laser-PAS50 in
patients with PD, and prominently in those with chronic pain,
which point to abnormal pain-motor integration. In addition, given
that a number of experimental and clinical studies have demon-
strated that invasive as well as non-invasive motor cortex stimu-
lation induce significant pain relief in patients with pain [83e87],
our findings provide further information for designing new thera-
peutic strategies with non-invasive brain stimulating protocols for
treating chronic pain in PD.Conflict of interest
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